Global Blood Profile

42.05
USD 0.95  2.31%
38%
75%

Exercise or conversion by Hing Sham of 4062 shares of Global Blood subject to Rule 16b-3

Global Blood Therapeutics insider trading alert for exercise of stock option (right to buy) by Hing Sham, Senior Vice President Chemistry, on July 17, 2018. This event was filed by Global Blood Therapeutics with SEC on 2015-08-19. Statement of changes in beneficial ownership - SEC Form 4. Hing Sham is currently serves as senior vice president - chemistry of Global Blood Therape [view details]   

Global Blood Summary

Global Blood Therapeutics (GBT) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 147 people. Global Blood is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with total capitalization of 2.11 B. Global Blood Therapeutics runs under Healthcare sector within Biotechnology industry. This company has 51.83 M outstanding shares of which 4.7 M shares are currently shorted by investors with about 5.57 days to cover shorted positions. ADVANCED BATTERY has about 543.59 M in cash with (107.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.49.
Check Global Blood Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 42.05HorizonTargetOdds Above 42.05
46.98%30 days 42.05 52.78%
Based on normal probability distribution, the odds of Global Blood to move above current price in 30 days from now is about 52.78% (This Global Blood Therapeutics probability density function shows the probability of Global Blood Stock to fall within a particular range of prices over 30 days) .

Top Holders

Selected Global Blood Therapeutics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Global Blood Against Markets

Risk Adjusted
Performance Score (0 to 100)
1 
Chance of
Financial Distress (0 to 100%)
54 
Equity ratings for Global Blood Therapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California. Global Blood operates under Biotechnology classification in USA and traded on NASDAQ. It employs 147 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Global Blood Therape SEC Filings
Global Blood SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameGlobal Blood Therapeutics
President CEO, DirectorTed LoveView All
Thematic Classifications
Active Investing Ideas
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationCALIFORNIA U.S.A
Business Address171 Oyster Point Boulevard
ExchangeBATS Exchange
CIK Number0001629137
CUSIP37890U108
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.gbt.com
Phone650 741 7700
CurrencyUSD - US Dollar

Did you try this?

Run Portfolio Suggestion Now
   

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
All  Next Launch Portfolio Suggestion

Global Blood Corporate Directors

Michael Bonney Director
Mark Perry Independent Director
Philip Pizzo Director, Ph.D
Please also check Risk vs Return Analysis. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.